Mark Kotter, bit.bio CEO

November 5, 2021 10:42 AM EDTUpdated 11:24 AM

Cell therapy startup bit.bio adds $100M+ to its coffers and some impressive names to its board of directors

Nicole DeFeudis

Editor

Bit.bio CEO Mark Kotter says the last major revolution in biopharma occurred around the 1980s, when antibodies — or, as some

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

Revolution’s KRAS drugs appear competitive in several lung cancer settings

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

Sanofi scraps IGM deal; Lilly to pay $250M to continue work with Purdue University

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges